Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: asai n. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N. Kojima T, et al. Among authors: asai n, asai s. Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302. Epub 2014 Aug 7. Rheumatology (Oxford). 2015. PMID: 25102861
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N. Kobayakawa T, et al. Among authors: asai n, asai s. Mod Rheumatol. 2015 Mar;25(2):251-6. doi: 10.3109/14397595.2014.953668. Epub 2014 Sep 11. Mod Rheumatol. 2015. PMID: 25211402
Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N. Takahashi N, et al. Among authors: asai n, asai s. J Rheumatol. 2015 May;42(5):786-93. doi: 10.3899/jrheum.141288. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834204
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D, Saito K, Kaneko A, Yabe Y, Takagi H, Oguchi T, Miyake H, Watanabe T, Hayashi M, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Takemoto T, Terabe K, Asai N, Yoshioka Y, Ishiguro N, Kojima T. Takahashi N, et al. Among authors: asai n, asai s. Rheumatol Int. 2015 Oct;35(10):1707-16. doi: 10.1007/s00296-015-3283-4. Epub 2015 May 20. Rheumatol Int. 2015. PMID: 25991396
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Yoshioka Y, Takahashi N, Kaneko A, Hirano Y, Kanayama Y, Kanda H, Takagi H, Ito T, Kato T, Saito K, Funahashi K, Asai S, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. Yoshioka Y, et al. Among authors: asai n, asai s. Mod Rheumatol. 2016;26(2):169-74. doi: 10.3109/14397595.2015.1069475. Epub 2015 Aug 19. Mod Rheumatol. 2016. PMID: 26140467
Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients.
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. Kojima T, et al. Among authors: asai n, asai s. Clin Rheumatol. 2016 Jan;35(1):219-25. doi: 10.1007/s10067-015-3135-3. Epub 2015 Dec 3. Clin Rheumatol. 2016. PMID: 26631102
428 results